Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

HAEMATOLOGICAL CANCER

Myeloid immune-checkpoint inhibition enters the clinical stage

Nature Reviews Clinical Oncology volume 16, pages 275–276 (2019)Cite this article

Subjects

The first-in-human study of anti-CD47 antibodies blocking CD47–SIRPα interactions in combination with rituximab in patients with non-Hodgkin lymphoma shows encouraging clinical responses accompanied with mild levels of toxicity. Inhibition of the CD47–SIRPα interaction might provide a generic method of promoting the effects of antitumour antibodies in a variety of cancer types. This reveals, for the first time, an innate immune checkpoint as a bona fide target for therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The CD47–SIRPα innate immune checkpoint.

References

  1. Matlung, H. L. et al. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Immunol. Rev. 276, 145–164 (2017).

    Article  CAS  Google Scholar 

  2. Chao, M. P. et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699–713 (2010).

    Article  CAS  Google Scholar 

  3. Oldenborg, P. A. et al. Role of CD47 as a marker of self on red blood cells. Science 288, 2051–2054 (2000).

    Article  CAS  Google Scholar 

  4. Zhao, X. W. et al. CD47-signal regulatory protein-alpha (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc. Natl Acad. Sci. USA 108, 18342–18347 (2011).

    Article  CAS  Google Scholar 

  5. Liu, X. et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21, 1209–1215 (2015).

    Article  CAS  Google Scholar 

  6. Advani, R. et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N. Engl. J. Med. 379, 1711–1721 (2018).

    Article  CAS  Google Scholar 

  7. Liu, J. et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLOS ONE 10, e0137345 (2015).

    Article  Google Scholar 

  8. Matlung, H. L. et al. Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Cell Rep. 23, 3946–3959 (2018).

    Article  CAS  Google Scholar 

  9. Bruhns, P. et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716–3725 (2009).

    Article  CAS  Google Scholar 

  10. Rösner, T. et al. Immune effector functions of human IgG2 antibodies against EGFR. Mol. Cancer Ther. https://doi.org/10.1158/1535-7163.MCT-18-0341 (2018).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

T.K.v.d.B. gratefully acknowledges research funding from the Dutch Cancer Society/KWF (#10300). T.V. gratefully acknowledges research funding from the German Research Foundation (DFG 124/9-1) and an intramural grant from the Christian-Albrechts-University.

Author information

Authors and Affiliations

  1. Sanquin Research, Landsteiner Laboratory, and the Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Amsterdam, Netherlands

    Timo K. van den Berg

  2. Division of Stem Cell Transplantation and Immunotherapy, Department of Internal Medicine II, Christian-Albrechts-University, Kiel, Germany

    Thomas Valerius

Authors
  1. Timo K. van den Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Valerius
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timo K. van den Berg.

Ethics declarations

Competing interests

T.K.v.d.B. is an inventor of a patent WO2009/131453, owned by Stichting Sanquin Bloedvoorziening, and is funded by a collaboration with Synthon Biopharmaceuticals BV. T.V. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van den Berg, T.K., Valerius, T. Myeloid immune-checkpoint inhibition enters the clinical stage. Nat Rev Clin Oncol 16, 275–276 (2019). https://doi.org/10.1038/s41571-018-0155-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-018-0155-3

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing